LANDFAR BIO-MEDICINE CO., LTD Financials Landfar Bio-medicine Co., Ltd
Equities
000504
CNE000000263
Healthcare Facilities & Services
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.93 CNY | +1.32% |
|
+0.43% | -40.26% |
Valuation
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 7,322 | 3,885 | 2,518 | 3,814 | 5,795 | 3,627 |
| Enterprise Value (EV) 1 | 7,359 | 3,980 | 2,524 | 4,018 | 5,950 | 3,643 |
| P/E ratio | -196 x | -113 x | 135 x | 408 x | -310 x | -291 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 109 x | 40.7 x | 18.8 x | 21.7 x | 37 x | 18.1 x |
| EV / Revenue | 109 x | 41.7 x | 18.8 x | 22.9 x | 38 x | 18.2 x |
| EV / EBITDA | -293 x | -341 x | -329 x | 169 x | -315 x | -217 x |
| EV / FCF | -1,018 x | -151 x | 459 x | -15.7 x | 59.5 x | 26 x |
| FCF Yield | -0.1% | -0.66% | 0.22% | -6.36% | 1.68% | 3.85% |
| Price to Book | 297 x | -379 x | 137 x | 144 x | 348 x | 263 x |
| Nbr of stocks (in thousands) | 311,574 | 311,574 | 311,574 | 311,574 | 311,574 | 311,574 |
| Reference price 2 | 23.50 | 12.47 | 8.080 | 12.24 | 18.60 | 11.64 |
| Announcement Date | 4/27/18 | 4/29/19 | 4/26/20 | 3/30/21 | 4/29/22 | 4/20/23 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net sales 1 | 67.39 | 95.38 | 134.2 | 175.6 | 156.6 | 200.3 |
| EBITDA 1 | -25.14 | -11.67 | -7.67 | 23.71 | -18.86 | -16.79 |
| EBIT 1 | -27.45 | -16.62 | -13.14 | 20.57 | -21.94 | -19.71 |
| Operating Margin | -40.74% | -17.42% | -9.79% | 11.71% | -14.01% | -9.84% |
| Earnings before Tax (EBT) 1 | -35.79 | -35.85 | 17.45 | 18.97 | -30.23 | -21.56 |
| Net income 1 | -37.12 | -35.19 | 18.81 | 8.155 | -19.13 | -12.69 |
| Net margin | -55.08% | -36.89% | 14.02% | 4.64% | -12.21% | -6.34% |
| EPS 2 | -0.1200 | -0.1100 | 0.0600 | 0.0300 | -0.0600 | -0.0400 |
| Free Cash Flow 1 | -7.23 | -26.38 | 5.501 | -255.6 | 99.98 | 140.2 |
| FCF margin | -10.73% | -27.65% | 4.1% | -145.61% | 63.83% | 69.98% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | 29.25% | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 4/27/18 | 4/29/19 | 4/26/20 | 3/30/21 | 4/29/22 | 4/20/23 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 36.6 | 95 | 6.06 | 204 | 154 | 16.5 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | -1.454 x | -8.145 x | -0.7903 x | 8.602 x | -8.18 x | -0.983 x |
| Free Cash Flow 1 | -7.23 | -26.4 | 5.5 | -256 | 100 | 140 |
| ROE (net income / shareholders' equity) | -34.8% | -32.2% | 16.4% | 11.8% | -27% | -31.3% |
| ROA (Net income/ Total Assets) | -4.86% | -2.78% | -2.69% | 3.12% | -2.26% | -2.03% |
| Assets 1 | 763.6 | 1,266 | -699.9 | 261.5 | 847.8 | 624.6 |
| Book Value Per Share 2 | 0.0800 | -0.0300 | 0.0600 | 0.0900 | 0.0500 | 0.0400 |
| Cash Flow per Share 2 | 0.5300 | 0.1900 | 0.2200 | 0.2200 | 0.4900 | 0.7000 |
| Capex 1 | 1.03 | 9.3 | 2.57 | 4.47 | 32 | 16.9 |
| Capex / Sales | 1.53% | 9.75% | 1.92% | 2.54% | 20.41% | 8.46% |
| Announcement Date | 4/27/18 | 4/29/19 | 4/26/20 | 3/30/21 | 4/29/22 | 4/20/23 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -40.26% | 316M | |
| -17.89% | 8.25B | |
| +39.20% | 3.58B | |
| -39.11% | 2.46B | |
| -8.06% | 2.46B | |
| -7.35% | 2.38B | |
| -12.61% | 1.81B | |
| -19.01% | 1.55B | |
| -40.66% | 1.21B | |
| +7.56% | 1.11B |
- Stock Market
- Equities
- 000504 Stock
- Financials Landfar Bio-medicine Co., Ltd
